Article 1 to 6 out of 6 concerning Oxford Genome Sciences (UK) Ltd
Oxford Genome Sciences announces new Therapeutic Antibody Deal with Medarex(20 Sep 2007) New agreement to drive the development of OGeS' own pipeline of antibodies in cancer Oxford Genome Sciences (UK) Ltd (OGeS) announced a second partnering agreement with Medarex, Inc. This new agreement provides OGeS with broad access to Medarex's fully human antibody technology and will potentially enable OGeS to accelerate the ...
Oxford Genome Sciences and University of Oxford to develop new clinical biomarkers for colorectal cancer(13 Apr 2006) OGeS joins consortium focused on the development of new personalised management of colorectal cancer Oxford Genome Sciences (UK) Ltd (OGeS) announced that it has entered into collaboration with the Department of Clinical Pharmacology at the University of Oxford to discover new clinical biomarkers for colorectal cancer (CRC).The collaboration forms ...
Biosite and Oxford Genome Sciences announce collaboration in colorectal cancer(07 Apr 2006) Biosite Incorporated and Oxford Genome Sciences (UK) Ltd. (OGeS) announced a collaboration for the evaluation of protein-based disease markers for colorectal cancer. The markers could be used for the development of potential blood-based diagnostic ...
Oxford Genome Sciences appoints Jeff Warren(06 Jul 2005) Oxford Genome Sciences (UK) Ltd (OGeS) announced the appointment of Jeff Warren as its first non-executive director. Mr Warren brings nearly 30 years financial management experience, including high level corporate governance and regulatory ...
Top
